Shaily Healthcare becomes largest business with 55% Q2 share
Key highlights
- Shaily Healthcare revenue rose 78% year-on-year to Rs 175 crore in Q2 FY27 and represented 55% of consolidated revenue.
- Consumer revenue was Rs 116 crore in Q2 FY27, down 14% year-on-year and flat sequentially.
- Shaily delivered 10.4 million devices in Q2 FY27 and said it remained on track to exceed 36 million for FY27.
- Q2 FY27 consolidated revenue was Rs 320 crore, up 24% year-on-year, while EBITDA rose 25% to Rs 102 crore.
powered by IRIS

Shaily Engineering Plastics Limited made Healthcare its largest business in Q2 FY27, with the segment contributing 55% of record quarterly revenue after rising 78% year-on-year to Rs 175 crore. The shift from Healthcare’s 38% revenue share a year earlier drove consolidated revenue to Rs 320 crore, up 24%.
Know Shaily Engineering Plastics inside out
Results, valuation, peers and who's buying, in one view.
How did Shaily’s revenue mix change in Q2 FY27?
Shaily’s revenue mix changed decisively toward Healthcare in Q2 FY27, as Healthcare generated Rs 175 crore, or 55% of the Rs 320 crore consolidated total, compared with a 38% share in Q2 FY26. Healthcare revenue increased from Rs 99 crore a year earlier, adding Rs 76 crore of the company’s Rs 63 crore increase in consolidated quarterly revenue.
Consumer remained the second-largest segment at Rs 116 crore, but its revenue was 14% lower year-on-year and flat sequentially. Industrial revenue was Rs 29 crore, up 23% year-on-year from Rs 23 crore, supported by Automotive, Appliances and Consumer Electronics customers. This meant quarterly growth was concentrated in Healthcare rather than spread evenly across the three reported segments.
The same divergence appeared in the first half. Healthcare revenue reached Rs 318 crore in H1 FY27, up 81% from Rs 176 crore in H1 FY26, while Consumer revenue fell 19% to Rs 231 crore from Rs 286 crore. Industrial rose 24% to Rs 51 crore from Rs 41 crore, leaving Healthcare as the principal source of Shaily’s reported H1 segment growth.
What powered Shaily Healthcare’s 78% growth?
Shaily said Q2 FY27 Healthcare growth was led by pen-injector platforms, particularly glucagon-like peptide-1, or GLP-1, programmes, alongside steady insulin and other-therapy volumes. The company delivered 10.4 million devices during the quarter and said it remained on track to exceed its full-year guidance of 36 million devices.
Management linked the opportunity to generic GLP-1 launches and wider patient access after semaglutide patent expiries in initial markets. It cited launches in India in March, approval of a generic in Canada in April and approval of Brazil’s first generic in August. Shaily’s stated mechanism is that lower therapy prices can increase demand for the drug-delivery devices it supplies.
The company also signed two new contracts for its Healthcare platforms during the quarter and introduced the Toby Reusable auto-injector for next-generation GLP-1 therapies. The device uses a single-use pre-filled-syringe pod attached to a mechanism retained by the patient for more than 200 injections, rather than replacing the full device after each use.
Management said its initial assessment indicates Toby Reusable is conservatively 70% more sustainable than a disposable two-step auto-injector. It said the pod is made from a single material and can use recycled material, while the reusable format is designed to reduce material consumption, energy use, shipping and cold-chain requirements. These are product-design claims from Shaily, not reported sales or profitability outcomes.
Why is Consumer still below last year’s revenue?
Shaily’s Consumer segment remained below last year’s level because demand for home furnishings in Europe and the United States was subdued, according to management. Consumer revenue of Rs 116 crore in Q2 FY27 was down 14% year-on-year, although it was unchanged sequentially for a second quarter of stabilisation.
Management said geopolitical developments in West Asia continued to affect freight costs and polymer prices in the quarter. Shaily said it responded through pricing discipline, procurement efficiencies and a favourable product mix, prioritising margin resilience and quality of returns rather than volume-led Consumer growth. The company also received confirmation for one new product from an existing customer and higher volumes for an existing product from another customer.
A few Consumer product lines, described by management as a relatively small part of the segment, continued to grow rapidly. But the H1 comparison shows the broader gap: Consumer revenue was Rs 231 crore in H1 FY27 versus Rs 286 crore in H1 FY26, a Rs 55 crore decline. That decline was more than offset by Healthcare’s Rs 142 crore H1 increase.
Got a follow-up? Ask IRIS
How did the business shift affect Shaily’s operations and profit?
Shaily reported that the higher-value Healthcare contribution lifted machine utilisation to 52.5% in Q2 FY27 from 47.8% a year earlier. Consolidated quarterly revenue rose 24% year-on-year and 14% sequentially to Rs 320 crore, while earnings before interest, tax, depreciation and amortisation, or EBITDA, increased 25% year-on-year to Rs 102 crore.
The Q2 EBITDA margin was 31.9%, compared with 31.8% in Q2 FY26, while gross margin recovered to 60%, about 70 basis points above the prior-year quarter. Profit after tax rose 20% to Rs 61 crore from Rs 51 crore, though the profit-after-tax margin declined to 19.2% from 20.0%.
For H1 FY27, consolidated revenue increased 19% to Rs 600 crore from Rs 503 crore and EBITDA grew 22% to Rs 185 crore from Rs 152 crore. The H1 EBITDA margin improved 60 basis points to 30.8%, while profit after tax rose 18% to Rs 109 crore and its margin moved to 18.2% from 18.4%. Exports represented 62.9% of H1 revenue, down from 71.7%, which management attributed primarily to Healthcare supplies to Indian pharmaceutical customers serving global markets.
What does Shaily plan to do next in Healthcare and other segments?
Shaily’s stated H2 FY27 priorities are to ramp newly commissioned capacity, exceed its 36 million-device full-year guidance, develop emergency-use and oncology platforms, progress Consumer Electronics and Semiconductor Packaging, and maintain margin discipline. In Healthcare, management said it is broadening beyond GLP-1 into emergency use and oncology, where devices must handle use in stressful settings or larger volumes at higher viscosities.
In Industrial, Shaily received confirmation for seven new power-tool products and new knobs for an Appliance customer during Q2 FY27. Semiconductor Tray revenue is expected to commence in Q4 FY27 from the existing facility, with trial production of Semiconductor Packaging planned for Q3 FY27 and commercial shipments expected in Q4 FY27. Commercial Consumer Electronics supplies have started, with production of five components awarded by a new customer being scaled progressively.
Management said capacity expansion for Consumer Electronics and Semiconductor Packaging would be aligned with customer commitments and the pace of business development. It also said these two areas could provide a significant scale-up opportunity over the next 36 months, but did not quantify revenue, capital expenditure or customer commitments for that potential expansion.
Conclusion
Shaily’s Q2 FY27 result shows a clear business-mix change: Healthcare rose from 38% to 55% of revenue in one year and supplied Rs 175 crore of the Rs 320 crore quarterly total. Pen-injector demand, especially GLP-1 programmes, supported Healthcare’s 78% growth, while Consumer remained at Rs 116 crore, 14% below the prior-year period despite sequential stabilisation.
The next disclosed markers are device deliveries against the more-than-36-million full-year target, capacity ramp-up and the planned Q3 FY27 Semiconductor Packaging trial production followed by expected Q4 FY27 commercial shipments. Investors can also watch whether the two new Healthcare platform contracts, the Toby Reusable launch and expansion into emergency use and oncology translate into disclosed customer programmes or revenue.


